Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The analysis of net income from 2019 to 2023 reveals a divergence between reported and adjusted figures, reflecting the impact of mark-to-market adjustments on available-for-sale securities. While reported net income followed a trajectory of initial growth followed by a gradual decline, adjusted net income experienced significant volatility, particularly between 2021 and 2022.
- Reported Net Income Trends
- Reported net income attributable to Humana increased from 2,707 million USD in 2019 to a peak of 3,367 million USD in 2020. Subsequently, a steady downward trend was observed, with values decreasing to 2,933 million USD in 2021, 2,806 million USD in 2022, and 2,489 million USD in 2023.
- Adjusted Net Income Volatility
- Adjusted net income demonstrated more pronounced fluctuations than reported net income. After peaking at 3,601 million USD in 2020, the figure declined to 2,578 million USD in 2021 and reached a minimum of 1,460 million USD in 2022. This was followed by a substantial recovery in 2023, where adjusted net income rose to 2,794 million USD.
- Mark-to-Market Adjustment Impact
- The variance between reported and adjusted net income highlights the effect of mark-to-market adjustments. Positive adjustments were present in 2019, 2020, and 2023, as adjusted net income exceeded reported net income in those years. In contrast, negative adjustments occurred in 2021 and 2022. The most significant divergence took place in 2022, where adjusted net income was 1,346 million USD lower than reported net income, indicating a substantial negative adjustment related to the valuation of available-for-sale securities.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Humana Inc., Profitability Ratios: Reported vs. Adjusted
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Profitability and return metrics exhibit a general downward trend over the five-year period, following a peak in 2020. While reported figures show a more linear decline, adjusted metrics demonstrate significant volatility, characterized by a sharp contraction in 2022 followed by a partial recovery in 2023.
- Net Profit Margins
- Reported net profit margins declined steadily from a peak of 4.43% in 2020 to 2.36% in 2023. Adjusted net profit margins followed a more volatile path; after peaking at 4.74% in 2020, they dropped sharply to 1.58% by 2022 before recovering to 2.65% in 2023. This suggests that non-recurring items or specific accounting adjustments had a more pronounced negative impact on normalized profitability in 2022 than in subsequent periods.
- Return on Equity (ROE)
- Reported ROE decreased from 24.53% in 2020 to 15.31% in 2023. In contrast, adjusted ROE experienced a more severe decline, falling from 26.23% in 2020 to a low of 9.54% in 2022. However, a strong rebound is observed in 2023, with adjusted ROE rising to 17.18%, surpassing the reported ROE for that same year.
- Return on Assets (ROA)
- Reported ROA shows a consistent downward trajectory from 9.63% in 2020 to 5.29% in 2023. Adjusted ROA mirrored the trend seen in ROE, dropping from 10.30% in 2020 to 3.39% in 2022, before recovering to 5.94% in 2023.
A notable divergence is observed between reported and adjusted figures starting in 2021. In 2022, the adjusted metrics were significantly lower than the reported metrics across all categories, indicating that the adjustments removed gains or recognized expenses that bolstered the reported results. By 2023, the trend reversed for ROE and ROA, where adjusted performance improved while reported performance continued to deteriorate, suggesting that the underlying operational profitability improved relative to the reported accounting figures.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 Net profit margin = 100 × Net income attributable to Humana ÷ External revenues
= 100 × 2,489 ÷ 105,305 = 2.36%
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Humana ÷ External revenues
= 100 × 2,794 ÷ 105,305 = 2.65%
The financial performance from 2019 to 2023 is characterized by a peak in profitability in 2020 followed by a period of significant volatility and a subsequent partial recovery in adjusted metrics.
- Adjusted Net Profit Margin Trends
- The adjusted net profit margin experienced a peak of 4.74% in 2020, followed by a sharp contraction over the next two years, reaching a low of 1.58% in 2022. A recovery occurred in 2023, with the margin increasing to 2.65%, although it remained well below the levels observed in 2019 and 2020.
- Comparative Analysis of Net Income
- Reported net income exhibited a more gradual decline from its 2020 peak of US$ 3,367 million to US$ 2,489 million in 2023. In contrast, adjusted net income showed higher volatility, dropping precipitously from US$ 3,601 million in 2020 to US$ 1,460 million in 2022, before rebounding to US$ 2,794 million in 2023.
- Profitability Margin Divergence
- A divergence is noted between reported and adjusted profit margins. While the reported net profit margin declined steadily from 4.43% in 2020 to 2.36% in 2023, the adjusted margin displayed a recovery pattern between 2022 and 2023. This suggests that non-recurring items significantly impacted the net results during the 2021-2022 period, as adjusted net income fell substantially below reported figures in those years before exceeding reported figures in 2023.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROE = 100 × Net income attributable to Humana ÷ Stockholders’ equity
= 100 × 2,489 ÷ 16,262 = 15.31%
2 Adjusted ROE = 100 × Adjusted net income attributable to Humana ÷ Stockholders’ equity
= 100 × 2,794 ÷ 16,262 = 17.18%
Financial performance from 2019 to 2023 is characterized by a general decline in reported profitability and a high degree of volatility in adjusted metrics. While reported figures show a steady downward trend after a 2020 peak, the adjusted figures indicate a significant contraction followed by a partial recovery in the final year of the period.
- Net Income Analysis
- Reported net income attributable to the company peaked in 2020 at US$ 3,367 million before declining steadily to US$ 2,489 million by 2023. Adjusted net income exhibited more pronounced fluctuations; after reaching a high of US$ 3,601 million in 2020, it dropped precipitously to US$ 1,460 million in 2022—a decrease of approximately 59.5% from the 2020 peak—before rebounding strongly to US$ 2,794 million in 2023.
- Return on Equity (ROE) Trends
- Reported ROE experienced a consistent contraction following its 2020 peak of 24.53%, ending the period at 15.31% in 2023. Adjusted ROE demonstrated more severe variance, falling from 26.23% in 2020 to a low of 9.54% in 2022. The adjusted ROE then recovered to 17.18% in 2023, indicating that while the long-term trend is lower than 2019-2020 levels, the most recent period shows a restoration of adjusted efficiency.
- Comparative Divergence
- A notable divergence between reported and adjusted metrics is observed in 2022, where adjusted ROE fell significantly below reported ROE (9.54% compared to 18.33%). By 2023, this trend reversed, with adjusted ROE exceeding reported ROE (17.18% compared to 15.31%), suggesting that specific adjustments had a negative impact on perceived performance in 2022 but provided a more favorable view of underlying profitability in 2023.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROA = 100 × Net income attributable to Humana ÷ Total assets
= 100 × 2,489 ÷ 47,065 = 5.29%
2 Adjusted ROA = 100 × Adjusted net income attributable to Humana ÷ Total assets
= 100 × 2,794 ÷ 47,065 = 5.94%
The financial performance from 2019 to 2023 exhibits a general decline in asset efficiency and profitability, characterized by a peak in 2020 followed by significant volatility in adjusted metrics.
- Net Income Trajectory
- Reported net income peaked in 2020 at 3,367 million US$ before entering a steady decline to 2,489 million US$ by 2023. Adjusted net income demonstrated greater volatility, reaching a high of 3,601 million US$ in 2020 and experiencing a sharp contraction to 1,460 million US$ in 2022, followed by a recovery to 2,794 million US$ in 2023.
- Reported Return on Assets (ROA)
- A consistent downward trend is observed in the reported ROA after 2020. Following a peak of 9.63% in 2020, the ratio declined to 6.61% in 2021 and continued to erode, reaching a five-year low of 5.29% by the end of 2023. This indicates a diminishing ability to generate profit from the total asset base on a reported basis.
- Adjusted Return on Assets (ROA)
- The adjusted ROA reflects a more volatile pattern than the reported figure. High levels of 10.41% in 2019 and 10.30% in 2020 were followed by a steep decline to 5.81% in 2021 and a nadir of 3.39% in 2022. However, 2023 saw a notable rebound to 5.94%, suggesting that while underlying operational efficiency faced severe pressure in 2022, some recovery was achieved in the following period.
- Comparative Analysis of Reported and Adjusted Metrics
- A divergence between reported and adjusted ROA is evident in 2023; while the reported ROA continued its descent to 5.29%, the adjusted ROA rose to 5.94%. This suggests that non-recurring items or specific accounting adjustments negatively impacted the reported results more heavily than the adjusted operational view. Furthermore, the gap between the two metrics was most pronounced in 2022, where adjusted ROA fell significantly below reported ROA, indicating that adjustments for that period substantially reduced the perceived return on assets.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?